Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression
Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression
复制标题
DOI：
10.1016/j.ejcts.2009.05.056
复制
发表时间：
2010-02-01
影响因子：
3.4
通讯作者：
Kawahara, Katsunobu
中科院分区：
文献类型：
--
作者：
Takeno, Shinsuke;Yamashita, Shin-ichi;Kawahara, Katsunobu
目的：本研究探讨生存素在食管鳞状细胞癌（ESCC）中的表达及其临床病理意义。此外，我们还用免疫组化方法检测了抗凋亡参数在食管鳞癌中的生物学作用。患者和方法：受试者包括71例ESCC手术后随访5年的患者，并进行化学分析，以检查生存素表达的临床病理影响。另外，37例新鲜冷冻的食管鳞癌标本，最近获得的有关剪接变异体的表达，使用逆转录聚合酶链反应（RT-PCR）进行了检查。结果：免疫组化Survivin蛋白在食管鳞癌组织中的阳性表达率为14.1%（10/22），胞浆阳性表达率为31.0%（22/22）。核表达显示没有临床病理学意义，但胞质表达与组织学分化（p = 0.002）和肿瘤浸润（p = 0.073）相关，并在单变量（p = 0.0184）和多变量（p = 0.0299）分析中显示预后影响。RT-PCR检测Survivin、Survivin-2B和Survivin-deltaEx 3 mRNA的阳性率分别为83.8%（31/31）、62.2%（23/23）和70.3%（26/26）。生存素-2B水平与组织分化显著相关（p = 0.038），但任何mRNA与临床病理因素之间均未发现其他显著意义。结论：Survivin作为一种抗凋亡分子生物学因子，其表达对食管鳞癌预后判断有一定价值。抑制survivin可能是ESCC的一种有效的分子生物学治疗方法。(C)2009年欧洲胸外科协会。Elsevier B. V.出版，保留所有权利。
Purpose: The present study examined the clinicopathological impact of survivin expression in oesophageal squamous cell carcinoma (ESCC). In addition, the biological role of anti-apoptosis parameter in ESCC was examined immunohistochemically. Patients and method: Subjects comprised 71 patients followed up for 5 years after surgery for ESCC and analysed immunohistochemically to examine the clinicopathological impact of survivin expression. Separately, 37 fresh frozen samples of ESCC obtained recently were examined concerning splicing variant expression of survivin using reverse-transcription polymerase chain reaction (RT-PCR). Results: Immunohistochemical survivin expression was detected in the nuclei of 10 ESCC specimens (14.1%) and cytoplasm of 22 specimens (31.0%). Nuclear expression displayed no clinicopathological implications, but cytoplasmic expression correlated with histological differentiation (p = 0.002) and tumour invasion (p = 0.073) and showed prognostic impacts in univariate (p = 0.0184) and multivariate (p = 0.0299) analyses. Survivin, survivin-2B and survivin-deltaEx3 mRNA were amplified in 31 (83.8%), 23 (62.2%) and 26 (70.3%) specimens, respectively, by RT-PCR. Survivin-2B level related significantly with histological differentiation (p = 0.038), but no other significant implication was identified between any mRNA and clinicopathological factors. Conclusion: As a molecular biological anti-apoptotic factor, survivin expression was of use in assessing prognosis in ESCC. Inhibition of survivin may be useful as a molecular biological therapy in ESCC. (C) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.